{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:23:41Z","timestamp":1793118221631,"version":"4.5.0"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T00:00:00Z","timestamp":1556496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Immune-related adverse events (irAEs) have emerged as a serious clinical issue in the use of immune checkpoint inhibitors (ICIs). Risk factors for irAEs remain controversial. Therefore, we studied sex differences in irAEs in patients treated with anti-programmed cell death protein 1 (PD-1) therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>All patients with metastatic melanoma and non-small cell lung cancer (NSCLC) treated with anti-PD-1 therapy at Mayo Clinic Rochester and Florida from 2015 to 2018 were reviewed. Kaplan-Meier method and log-rank test was used for time-to-event analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In 245 patients with metastatic melanoma, premenopausal women were more likely to experience irAEs (all grades) compared with postmenopausal women and men (67% vs. 60% vs. 46%), primarily because of an increase in endocrinopathies (33% vs. 12% vs. 10%, respectively). In patients with NSCLC (231 patients), women (all ages) were also more likely to develop irAEs of all grades (48% vs. 31%). Women with NSCLC were more likely to develop pneumonitis (11% vs. 4%) and endocrinopathies (14% vs. 5%). No differences in grade \u22653 toxicities were seen across sexes in both cohorts, but women were more likely to receive systemic steroids for the treatment of irAEs compared with men. Better progression-free-survival was observed in women with NSCLC and irAEs (10 months vs. 3.3 months) compared with women without irAEs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Women with metastatic melanoma and NSCLC are more likely to experience irAEs compared with men. We also observed differences between sexes in the frequency of certain irAEs. Larger studies are needed to investigate the mechanisms underlying these associations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>The results of this study suggest that women may be at a higher risk for immune-related adverse events (irAEs) compared with men when treated with anti-programmed cell death protein 1 therapy. In addition, women were more likely to develop certain irAEs, including endocrinopathies and pneumonitis. Close follow-up of women undergoing treatment with immune checkpoint inhibitors will allow clinicians to diagnose these treatment-related complications early, potentially reducing their associated morbidity and mortality. In addition, a possible association between irAEs and response to therapy was observed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0094","type":"journal-article","created":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T20:33:26Z","timestamp":1556570006000},"page":"e1148-e1155","source":"Crossref","is-referenced-by-count":122,"title":["Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?"],"prefix":"10.1093","volume":"24","author":[{"given":"Narjust","family":"Duma","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azzouqa","family":"Abdel-Ghani","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhartha","family":"Yadav","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine P.","family":"Hoversten","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clay T.","family":"Reed","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea N.","family":"Sitek","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Ann L.","family":"Enninga","sequence":"additional","affiliation":[{"name":"Division of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Paludo","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus Vera","family":"Aguilera","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Leventakos","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Lou","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Kottschade","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haidong","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Immunology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Mansfield","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Manochakian","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex A.","family":"Adjei","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana S.","family":"Dronca","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,4,29]]},"reference":[{"key":"2021122508115827900_onco12969-bib-0001","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/phar.1643","article-title":"Immune checkpoint inhibitors: New insights and current place in cancer therapy","volume":"35","author":"La-Beck","year":"2015","journal-title":"Pharmacotherapy"},{"key":"2021122508115827900_onco12969-bib-0002","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1158\/1078-0432.CCR-14-2959","article-title":"Immune checkpoint modulation for non-small cell lung cancer","volume":"21","author":"Soria","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2021122508115827900_onco12969-bib-0003","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.seminoncol.2010.09.005","article-title":"Immune checkpoint proteins: A new therapeutic paradigm for cancer\u2014Preclinical background: CTLA-4 and PD-1 blockade","volume":"37","author":"Weber","year":"2010","journal-title":"Semin Oncol"},{"key":"2021122508115827900_onco12969-bib-0004","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-l1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"key":"2021122508115827900_onco12969-bib-0005","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: A collaborative position paper","volume":"27","author":"Champiat","year":"2015","journal-title":"Ann Oncol"},{"key":"2021122508115827900_onco12969-bib-0006","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021122508115827900_onco12969-bib-0007","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"2021122508115827900_onco12969-bib-0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer"},{"key":"2021122508115827900_onco12969-bib-0009","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000247","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"2","author":"Varricchi","year":"2017","journal-title":"ESMO Open"},{"key":"2021122508115827900_onco12969-bib-0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195945","article-title":"Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab","volume":"13","author":"Dumenil","year":"2018","journal-title":"PloS One"},{"issue":"suppl 2","key":"2021122508115827900_onco12969-bib-0011","first-page":"1205","article-title":"SAT0715 risk factors of immune-related adverse events in patients treated with anti-PD-1 antibody pembrolizumab","volume":"77","author":"Eun","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"suppl 15","key":"2021122508115827900_onco12969-bib-0012","doi-asserted-by":"crossref","first-page":"2505a","DOI":"10.1200\/jco.2011.29.15_suppl.2505","article-title":"Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis","volume":"29","author":"Callahan","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122508115827900_onco12969-bib-0013","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1479-5876-11-75","article-title":"Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events","volume":"11","author":"Shahabi","year":"2013","journal-title":"J Transl Med"},{"issue":"suppl 15","key":"2021122508115827900_onco12969-bib-0014","doi-asserted-by":"crossref","first-page":"9096a","DOI":"10.1200\/jco.2014.32.15_suppl.9096","article-title":"Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab","volume":"32","author":"Schindler","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122508115827900_onco12969-bib-0015","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/nri2394","article-title":"The X-files in immunity: Sex-based differences predispose immune responses","volume":"8","author":"Fish","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"2021122508115827900_onco12969-bib-0016","doi-asserted-by":"crossref","first-page":"A479","DOI":"10.1016\/j.autrev.2011.11.022","article-title":"The influence of sex and gender on the immune response","volume":"11","author":"Oertelt-Prigione","year":"2012","journal-title":"Autoimmun Rev"},{"key":"2021122508115827900_onco12969-bib-0017","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/clin.1997.4412","article-title":"Epidemiology and estimated population burden of selected autoimmune diseases in the United States","volume":"84","author":"Jacobson","year":"1997","journal-title":"Clin Immunol Immunopathol"},{"key":"2021122508115827900_onco12969-bib-0018","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1568-9972(03)00006-5","article-title":"The epidemiology of autoimmune diseases","volume":"2","author":"Cooper","year":"2003","journal-title":"Autoimmun Rev"},{"key":"2021122508115827900_onco12969-bib-0019","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cellimm.2015.01.018","article-title":"Estrogen receptors regulate innate immune cells and signaling pathways","volume":"294","author":"Kovats","year":"2015","journal-title":"Cell Immunol"},{"key":"2021122508115827900_onco12969-bib-0020","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0091-6749(99)70503-8","article-title":"Estrogen enhances immunoglobulin production by human PBMCs","volume":"103","author":"Kanda","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"2021122508115827900_onco12969-bib-0021","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s12016-010-8203-5","article-title":"Estrogen receptors in immunity and autoimmunity","volume":"40","author":"Cunningham","year":"2011","journal-title":"Clin Rev Allergy Immunol"},{"key":"2021122508115827900_onco12969-bib-0022","author":"U.S. Department of Health and Human Services","year":"2009"},{"key":"2021122508115827900_onco12969-bib-0023","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune-related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"key":"2021122508115827900_onco12969-bib-0024","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/oxfordjournals.epirev.a036194","article-title":"Menopause: Its epidemiology and potential association with chronic diseases","volume":"17","author":"Sowers","year":"1995","journal-title":"Epidemiol Rev"},{"key":"2021122508115827900_onco12969-bib-0025","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0378-5122(95)00968-X","article-title":"The demography of menopause","volume":"23","author":"Hill","year":"1996","journal-title":"Maturitas"},{"key":"2021122508115827900_onco12969-bib-0026","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.maturitas.2010.04.015","article-title":"Defining menopausal status in epidemiologic studies: A comparison of multiple approaches and their effects on breast cancer rates","volume":"67","author":"Phipps","year":"2010","journal-title":"Maturitas"},{"key":"2021122508115827900_onco12969-bib-0027","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/GME.0000000000001199","article-title":"Amenorrhea after lung cancer treatment","volume":"26","author":"Cathcart-Rake","year":"2019","journal-title":"Menopause"},{"key":"2021122508115827900_onco12969-bib-0028","author":"Casper"},{"key":"2021122508115827900_onco12969-bib-0029","author":"Santoro","year":"2011"},{"key":"2021122508115827900_onco12969-bib-0030","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2021122508115827900_onco12969-bib-0031","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients' sex: A systematic review and meta-analysis","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol"},{"key":"2021122508115827900_onco12969-bib-0032","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.5904","article-title":"Association of patient sex with efficacy of immune checkpoint inhibitors and overall survival in advanced cancers: A systematic review and meta-analysis","author":"Wallis","year":"2019","journal-title":"JAMA Oncol"},{"key":"2021122508115827900_onco12969-bib-0033","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(18)30483-2","article-title":"Sex as a predictor of response to cancer immunotherapy","volume":"19","author":"McQuade","year":"2018","journal-title":"Lancet Oncol"},{"key":"2021122508115827900_onco12969-bib-0034","doi-asserted-by":"crossref","first-page":"e893","DOI":"10.1016\/j.cllc.2018.08.008","article-title":"Incidence, risk factors, and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer","volume":"19","author":"Owen","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"2021122508115827900_onco12969-bib-0035","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00432-018-2805-3","article-title":"Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: Long-term outcomes from a multi-institutional analysis","volume":"145","author":"Ricciuti","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"2021122508115827900_onco12969-bib-0036","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"2021122508115827900_onco12969-bib-0037","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005374","article-title":"SeXX matters in infectious disease pathogenesis","volume":"12","author":"vom Steeg","year":"2016","journal-title":"PLoS Pathog"},{"key":"2021122508115827900_onco12969-bib-0038","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1473-3099(10)70049-9","article-title":"The Xs and Y of immune responses to viral vaccines","volume":"10","author":"Klein","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"2021122508115827900_onco12969-bib-0039","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3389\/fimmu.2018.00552","article-title":"Sexual dimorphism of immune responses: A new perspective in cancer immunotherapy","volume":"9","author":"Capone","year":"2018","journal-title":"Front Immunol"},{"key":"2021122508115827900_onco12969-bib-0040","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.4049\/jimmunol.1000496","article-title":"B7-h1\u2013dependent sex-related differences in tumor immunity and immunotherapy responses","volume":"185","author":"Lin","year":"2010","journal-title":"J Immunol"},{"key":"2021122508115827900_onco12969-bib-0041","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0928-8244(03)00202-5","article-title":"Regulation of innate and adaptive immunity by the female sex hormones oestradiol and progesterone","volume":"38","author":"Beagley","year":"2003","journal-title":"FEMS Immunol Med Microbiol"},{"key":"2021122508115827900_onco12969-bib-0042","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nri2815","article-title":"The X chromosome in immune functions: When a chromosome makes the difference","volume":"10","author":"Libert","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"2021122508115827900_onco12969-bib-0043","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"2021122508115827900_onco12969-bib-0044","doi-asserted-by":"crossref","first-page":"99336","DOI":"10.18632\/oncotarget.22242","article-title":"The sexist behaviour of immune checkpoint inhibitors in cancer therapy?","volume":"8","author":"Botticelli","year":"2017","journal-title":"Oncotarget"},{"key":"2021122508115827900_onco12969-bib-0045","doi-asserted-by":"crossref","first-page":"J109","DOI":"10.1016\/j.jaut.2011.10.003","article-title":"Autoimmune disease and gender: Plausible mechanisms for the female predominance of autoimmunity","volume":"38","author":"Quintero","year":"2012","journal-title":"J Autoimmun"},{"key":"2021122508115827900_onco12969-bib-0046","doi-asserted-by":"crossref","first-page":"J287","DOI":"10.1016\/j.jaut.2009.11.015","article-title":"The implications of autoimmunity and pregnancy","volume":"34","author":"Borchers","year":"2010","journal-title":"J Autoimmun"},{"key":"2021122508115827900_onco12969-bib-0047","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.3201\/eid1011.040367","article-title":"Women and autoimmune diseases","volume":"10","author":"Fairweather","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"2021122508115827900_onco12969-bib-0048","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2006.12.004","article-title":"Gender as risk factor for autoimmune diseases","volume":"28","author":"Gleicher","year":"2007","journal-title":"J Autoimmun"},{"key":"2021122508115827900_onco12969-bib-0049","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1093\/humrep\/17.10.2715","article-title":"High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: A survey analysis","volume":"17","author":"Sinaii","year":"2002","journal-title":"Hum Reprod"},{"key":"2021122508115827900_onco12969-bib-0050","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/BOR.0b013e328277ef2a","article-title":"Estrogen and CD4+ T cells","volume":"19","author":"Pernis","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"2021122508115827900_onco12969-bib-0051","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1182\/blood-2003-10-3380","article-title":"17\u03b2-estradiol (E2) modulates cytokine and chemokine expression in human monocyte-derived dendritic cells","volume":"104","author":"Bengtsson","year":"2004","journal-title":"Blood"},{"key":"2021122508115827900_onco12969-bib-0052","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.4049\/jimmunol.176.5.2703","article-title":"Hormonal regulation of B cell development: 17\u03b2-estradiol impairs negative selection of high-affinity DNA-reactive B cells at more than one developmental checkpoint","volume":"176","author":"Grimaldi","year":"2006","journal-title":"J Immunol"},{"key":"2021122508115827900_onco12969-bib-0053","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1210\/er.2007-0001","article-title":"The complex role of estrogens in inflammation","volume":"28","author":"Straub","year":"2007","journal-title":"Endocr Rev"},{"key":"2021122508115827900_onco12969-bib-0054","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.autrev.2014.07.001","article-title":"Obesity in autoimmune diseases: Not a passive bystander","volume":"13","author":"Versini","year":"2014","journal-title":"Autoimmun Rev"},{"key":"2021122508115827900_onco12969-bib-0055","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/B978-0-12-384929-8.00027-7","volume-title":"The Autoimmune Diseases","author":"Taneja","year":"2014","edition":"5th ed"},{"key":"2021122508115827900_onco12969-bib-0056","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Ferrara","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021122508115827900_onco12969-bib-0057","doi-asserted-by":"crossref","first-page":"9573","DOI":"10.1073\/pnas.160099797","article-title":"Inhibition of IL-2-induced JAK-STAT signaling by glucocorticoids","volume":"97","author":"Bianchi","year":"2000","journal-title":"Proc Natl Acad Sci"},{"key":"2021122508115827900_onco12969-bib-0058","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2021122508115827900_onco12969-bib-0059","doi-asserted-by":"crossref","first-page":"9523a","DOI":"10.1200\/JCO.2017.35.15_suppl.9523","article-title":"Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL)","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122508115827900_onco12969-bib-0060","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1634\/theoncologist.2017-0384","article-title":"Association of immune-related adverse events with clinical benefit in patients with advanced non-small-cell lung cancer treated with nivolumab","volume":"23","author":"Toi","year":"2018","journal-title":"The Oncologist"},{"key":"2021122508115827900_onco12969-bib-0061","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: Characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2021122508115827900_onco12969-bib-0062","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.jtho.2017.08.022","article-title":"Early immune-related adverse events and association with outcome in advanced non\u2013small cell lung cancer patients treated with nivolumab: A prospective cohort study","volume":"12","author":"Teraoka","year":"2017","journal-title":"J Thorac Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0094","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0094","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/11\/e1148\/41919419\/oncolo_24_11_e1148.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/11\/e1148\/41919419\/oncolo_24_11_e1148.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T08:12:42Z","timestamp":1640419962000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/11\/e1148\/6439794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,29]]},"references-count":62,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,4,29]]},"published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0094","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11,1]]},"published":{"date-parts":[[2019,4,29]]}}}